Impact of preexisting interstitial lung disease on mortality in COVID-19 patients from the early pandemic to the delta variant epidemic: a nationwide population-based study

Koichi Miyashita,Hironao Hozumi,Kazuki Furuhashi,Eiji Nakatani,Yusuke Inoue,Hideki Yasui,Yuzo Suzuki,Masato Karayama,Noriyuki Enomoto,Tomoyuki Fujisawa,Naoki Inui,Toshiyuki Ojima,Takafumi Suda

DOI: https://doi.org/10.1186/s12931-024-02723-3

IF: 5.8

2024-02-22

Respiratory Research

Abstract:COVID-19 patients with preexisting interstitial lung disease (ILD) were reported to have a high mortality rate; however, this was based on data from the early stages of the pandemic. It is uncertain how their mortality rates have changed with the emergence of new variants of concern as well as the development of COVID-19 vaccines and treatments. It is also unclear whether having ILD still poses a risk factor for mortality. As COVID-19 continues to be a major concern, further research on COVID-19 patients with preexisting ILD is necessary.

respiratory system

What problem does this paper attempt to address?

The problem this paper attempts to address is whether patients with interstitial lung disease (ILD) still face a higher risk of death during the COVID-19 pandemic, particularly during the period from the wild-type to the delta variant. The research background indicates that in the early stages of the pandemic, the mortality rate of COVID-19 patients with ILD was high. However, it is unclear whether the mortality rate of these patients has changed with the emergence of new variants, vaccination, and the development of treatment methods. Therefore, this study aims to explore the changes in all-cause mortality of ILD patients at different stages of the pandemic by analyzing data from the national insurance claims database in Japan and to assess whether ILD remains an independent risk factor for death in COVID-19 patients.

The research methods include extracting data on adult COVID-19 patients from the national insurance claims database in Japan from January 2020 to August 2021 and dividing the patients into two groups: those with and without ILD. The researchers analyzed the all-cause mortality rates at different variant stages (wild-type, alpha, delta) and adjusted for factors such as age, gender, pandemic stage, and other comorbidities using a multivariable logistic regression model to evaluate the relationship between ILD and mortality.

The research results show that although the 60-day mortality rate of ILD patients decreased over time, ILD remained an independent risk factor for death at all stages of the pandemic. Specifically, the 60-day mortality rate of ILD patients decreased from 16.0% in the wild-type stage to 7.5% in the delta stage, but ILD patients always faced a higher risk of death compared to non-ILD patients. Additionally, different types of ILD had varying impacts on mortality, with idiopathic pulmonary fibrosis (IPF) patients having the highest mortality rate.

The conclusion is that despite changes in the COVID-19 environment, ILD patients still face a higher risk of death and should receive special attention in clinical management.